These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 21395580

  • 21. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A, Rowntree C.
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [Abstract] [Full Text] [Related]

  • 22. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV, Li Y, Younes A.
    Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
    [Abstract] [Full Text] [Related]

  • 23. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K.
    Cancer Res; 2005 Nov 15; 65(22):10536-44. PubMed ID: 16288046
    [Abstract] [Full Text] [Related]

  • 24. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 25. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J, Martín-Ventura JL.
    Cardiovasc Res; 2010 May 01; 86(2):330-7. PubMed ID: 20154064
    [Abstract] [Full Text] [Related]

  • 26. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 27. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A, Asano T, Ito K, Asano T.
    Int J Oncol; 2012 Jul 14; 41(1):46-52. PubMed ID: 22470109
    [Abstract] [Full Text] [Related]

  • 28. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
    Lee KH, Jang AH, Yoo CG.
    Am J Respir Cell Mol Biol; 2015 Sep 14; 53(3):412-21. PubMed ID: 25633180
    [Abstract] [Full Text] [Related]

  • 29. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
    Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS.
    J Pharmacol Exp Ther; 2009 Jul 14; 330(1):276-82. PubMed ID: 19329756
    [Abstract] [Full Text] [Related]

  • 30. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 31. Dopamine-induced toxicity is synergistically potentiated by simultaneous HSP-90 and Akt inhibition in oligodendrocyte progenitors.
    Hemdan S, Almazan G.
    J Neurochem; 2008 May 01; 105(4):1223-34. PubMed ID: 18194434
    [Abstract] [Full Text] [Related]

  • 32. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells.
    Yoshikawa N, Nemoto T, Satoh S, Maruta T, Yanagita T, Chosa E, Wada A.
    Neurochem Int; 2010 Jan 01; 56(1):42-50. PubMed ID: 19737590
    [Abstract] [Full Text] [Related]

  • 33. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Jan 01; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 34. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 35. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D, Marshall JC, Antecka E, Di Cesare S, Odashiro AN, Bakalian S, Fernandes BF, Burnier MN.
    Clin Cancer Res; 2008 Feb 01; 14(3):847-55. PubMed ID: 18245548
    [Abstract] [Full Text] [Related]

  • 36. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.
    Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L.
    Leuk Res; 2011 Sep 01; 35(9):1212-8. PubMed ID: 21632108
    [Abstract] [Full Text] [Related]

  • 37. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.
    Cancer Chemother Pharmacol; 2013 May 01; 71(5):1345-55. PubMed ID: 23564374
    [Abstract] [Full Text] [Related]

  • 38. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.
    Enomoto A, Fukasawa T, Takamatsu N, Ito M, Morita A, Hosoi Y, Miyagawa K.
    Eur J Cancer; 2013 Nov 01; 49(16):3547-58. PubMed ID: 23886587
    [Abstract] [Full Text] [Related]

  • 39. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    Anticancer Res; 2015 Oct 01; 35(10):5453-60. PubMed ID: 26408708
    [Abstract] [Full Text] [Related]

  • 40. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
    Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE.
    BMC Cancer; 2010 Sep 09; 10():481. PubMed ID: 20828379
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.